Protalix BioTherapeutics (PLX) Equity Average (2010 - 2026)
Protalix BioTherapeutics' quarterly Equity Average came in at $57.7 million in Q1 2026, up 30.58% year-on-year from $44.2 million in Q1 2025, and up 14.16% quarter-over-quarter from $50.6 million in Q4 2025.
Protalix BioTherapeutics has reported Equity Average for 17 years, with the latest figure at $57.7 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Average rose 30.58% year-over-year to $57.7 million; the trailing twelve-month figure through Mar 2026 stood at $57.7 million (up 30.58% YoY), and the FY2025 full-year result was $45.7 million, up 19.09% from the prior year.
- Equity Average for Q1 2026 stood at $57.7 million, up from $50.6 million in the prior quarter.
- The five-year high for Equity Average was $57.7 million in Q1 2026, with the low at -$11.1 million in Q4 2022.
- Average Equity Average over 5 years is $25.5 million, with a median of $31.7 million recorded in 2024.
- Year-over-year, Equity Average slumped 627.95% in 2022 and surged 757.76% in 2024.
- Tracing PLX's Equity Average over 5 years: stood at -$11.1 million in 2022, then jumped by 424.17% to $35.9 million in 2023, then grew by 5.34% to $37.8 million in 2024, then soared by 33.7% to $50.6 million in 2025, then gained by 14.16% to $57.7 million in 2026.
- The last three Equity Average figures came in at $57.7 million (Q1 2026), $50.6 million (Q4 2025), and $51.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 57.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57.73 Mn |
| Dec 31, 2025 | 50.57 Mn |
| Sep 30, 2025 | 51.41 Mn |
| Jun 30, 2025 | 47.56 Mn |
| Mar 31, 2025 | 44.21 Mn |
| Dec 31, 2024 | 37.82 Mn |
| Sep 30, 2024 | 30.51 Mn |
| Jun 30, 2024 | 29.18 Mn |
| Mar 31, 2024 | 31.68 Mn |
| Dec 31, 2023 | 35.91 Mn |
| Sep 30, 2023 | 38.62 Mn |
| Jun 30, 2023 | 20.00 Mn |
| Mar 31, 2023 | -4.82 Mn |
| Dec 31, 2022 | -11.08 Mn |
| Sep 30, 2022 | -10.70 Mn |
| Jun 30, 2022 | -8.69 Mn |
| Mar 31, 2022 | -6.76 Mn |
| Dec 31, 2021 | -2.91 Mn |
| Sep 30, 2021 | 2.03 Mn |
| Jun 30, 2021 | 9.17 Mn |
| Mar 31, 2021 | -6.27 Mn |
| Dec 31, 2020 | -30.18 Mn |
| Sep 30, 2020 | -34.04 Mn |
| Jun 30, 2020 | -32.82 Mn |
| Mar 31, 2020 | -50.60 Mn |
| Dec 31, 2019 | -70.59 Mn |
| Sep 30, 2019 | -69.17 Mn |
| Jun 30, 2019 | -63.67 Mn |
| Mar 31, 2019 | -56.37 Mn |
| Dec 31, 2018 | -50.41 Mn |
| Sep 30, 2018 | -45.34 Mn |
| Jun 30, 2018 | -39.09 Mn |
| Mar 31, 2018 | -32.45 Mn |
| Dec 31, 2017 | -27.76 Mn |
| Sep 30, 2017 | -23.37 Mn |
| Jun 30, 2017 | -44.57 Mn |
| Mar 31, 2017 | -39.21 Mn |
| Dec 31, 2016 | -12.53 Mn |
| Sep 30, 2016 | -11.54 Mn |
| Jun 30, 2016 | -2.66 Mn |
| Mar 31, 2016 | 6.76 Mn |
| Dec 31, 2015 | -28.82 Mn |
| Sep 30, 2015 | -66.82 Mn |
| Jun 30, 2015 | -63.15 Mn |
| Mar 31, 2015 | -58.38 Mn |
| Dec 31, 2014 | -44.59 Mn |
| Mar 31, 2014 | -30.26 Mn |
| Dec 31, 2013 | -21.83 Mn |
| Sep 30, 2013 | -14.35 Mn |
| Jun 30, 2013 | -9.13 Mn |
| Mar 31, 2013 | -4.82 Mn |
| Dec 31, 2012 | 707,500.00 |
| Sep 30, 2012 | 6.32 Mn |
| Jun 30, 2012 | 703,000.00 |
| Mar 31, 2012 | -16.27 Mn |
| Dec 31, 2011 | -21.72 Mn |
| Sep 30, 2011 | -13.03 Mn |
| Jun 30, 2011 | -2.00 Mn |
| Mar 31, 2011 | -3.31 Mn |
| Dec 31, 2010 | -7.43 Mn |
| Sep 30, 2010 | -2.55 Mn |